Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

20.81 +0.75 (+3.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,678
Open 20.14
Bid (Size) 13.50 (100)
Ask (Size) 27.95 (300)
Prev. Close 20.06
Today's Range 19.76 - 22.00
52wk Range 0.3900 - 45.00
Shares Outstanding 240,471,497
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire

Performance

YTD
-28.2%
-28.2%
1 Month
-13.7%
-13.7%
3 Month
-32.4%
-32.4%
6 Month
+25.7%
+25.7%
1 Year
+4196.9%
+4196.9%

More News

Read More
News headline image
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
From Equity Insider
Via GlobeNewswire
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Via Benzinga
News headline image
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314 ↗
Via Chartmill
Topics Earnings
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Via Chartmill

Frequently Asked Questions

Is Lyell Immunopharma, Inc. - Common Stock publicly traded?
Yes, Lyell Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Lyell Immunopharma, Inc. - Common Stock trade on?
Lyell Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lyell Immunopharma, Inc. - Common Stock?
The ticker symbol for Lyell Immunopharma, Inc. - Common Stock is LYEL on the Nasdaq Stock Market
What is the current price of Lyell Immunopharma, Inc. - Common Stock?
The current price of Lyell Immunopharma, Inc. - Common Stock is 20.81
When was Lyell Immunopharma, Inc. - Common Stock last traded?
The last trade of Lyell Immunopharma, Inc. - Common Stock was at 04/01/26 04:00 PM ET
What is the market capitalization of Lyell Immunopharma, Inc. - Common Stock?
The market capitalization of Lyell Immunopharma, Inc. - Common Stock is 5.00B
How many shares of Lyell Immunopharma, Inc. - Common Stock are outstanding?
Lyell Immunopharma, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.